CWBR CohBar is a clinical stage biotechnology company which develops mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases.
CWBR closed few months ago a $15.0 Million Offering of Common Stock and Warrants at $0.72, so this is a safe upside in my opinion if you want to enter now.
Cantor Fitzgerald brokerage has a $2.5 price target for it.